NVS near $149 as Feb. 4 earnings approach — what to watch
Zurich, January 31, 2026, 20:21 CET — Trading wrapped up
- Novartis’ U.S.-listed ADRs (NVS) ended Friday at $148.68, slipping roughly 0.1%
- Swiss drugmaker set to release its Q4 and full-year 2025 earnings on Feb. 4
- Analysts are zeroing in on key brand sales trends and 2026 guidance to gauge the next move
Novartis AG’s U.S.-listed ADRs — representing the Swiss shares — dipped 0.1% on Friday, closing at $148.68 after fluctuating between $148.05 and $149.89. Roughly 1.15 million ADRs were traded.
Markets are closed for the weekend, shifting focus to Novartis’ next update. The investor calendar pins February 4 for the fourth-quarter and full-year 2025 results, alongside the Annual Report 2025 release. A…
